The Top Line

Fierce Life Sciences
  • 0.0 (0)
  • BUSINESS NEWS
  • UPDATED WEEKLY
The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

  1. 3 DAYS AGO

    Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more

    In this week’s episode of "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. On stage, five extraordinary leaders shared their insights, experiences, and bold ideas shaping the future of healthcare and beyond. These honorees represent the five categories of this year’s Fierce 50: health equity, innovation, social impact, breakthroughs and patient advocacy. Each honoree brings powerful insights and inspiring stories to the table. From reimagining maternal healthcare and addressing antibiotic resistance to translating public health science, transforming healthcare with AI, and tackling rural health challenges, this panel highlights innovation and disruption at its finest. To learn more about the topics in this episode:  Fierce 50 of 2024 Fierce 50 of 2024 - Innovation Honorees Fierce 50 of 2024 - Health Equity Honorees Fierce 50 of 2024 - Social Impact Honorees Fierce 50 of 2024 - Breakthroughs Honorees  Fierce 50 of 2024 - Patient Advocacy Honorees  See omnystudio.com/listener for privacy information.

    40 min

  2. 13 DEC

    Novo Nordisk’s chief scientific officer looks to the future of GLP-1s

    GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms. In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma. To learn more about the topics in this episode: Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2 Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy See omnystudio.com/listener for privacy information.

    33 min

  3. 6 DEC

    What can we learn from 2024’s biotech IPOs?

    After a promising start to the year, the biotech IPO market picked up steam again late this summer, with notable offerings from companies like Upstream, Septerna and BioAge. But what does this mean for the sector? Is market enthusiasm truly returning, or are we just seeing a temporary rebound? To unpack these questions and look ahead to 2025, Fierce Biotech’s James Waldron chatted with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group.   To learn more about the topics in this episode:  Septerna's $288M IPO is another sign of the market warming to biotech investment BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq Upstream swells IPO to $255M as it prepares to join Nasdaq along with CAMP4 Kairos goes public with $6M IPO to fund trials of lead cancer drug See omnystudio.com/listener for privacy information.

    15 min

  4. 22 NOV

    Meet 2024’s fiercest women in life sciences

    Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life sciences—leaders who are transforming the industry with their innovation and impact. This year, our special report celebrates 10 women driving change in clinical research, business development, venture capital, and beyond. In this week's episode of "The Top Line," Fierce’s Andrea Park and Gabrielle Masson share the stories that stood out, the breakthroughs these women are championing, and why recognizing their achievements is more crucial than ever.  To learn more about the topics in this episode:  2024's Fiercest Women in Life Sciences Big Pharma's 10 highest-paid CEOs of 2023 See omnystudio.com/listener for privacy information.

    13 min

  5. 15 NOV

    Misconduct and the future of neurodegenerative disease research

    Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images.  In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct. To learn more about the topics in this episode:   NIH neuroscience leader committed research misconduct, agency investigation finds See omnystudio.com/listener for privacy information.

    15 min

  6. 8 NOV

    Dig into this year’s Fierce Biotech Graveyard, layoff numbers

    Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities.  In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.   They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.   To learn more about the topics in this episode:  The 2024 Biotech Graveyard Fierce Biotech Layoff Tracker 2024 See omnystudio.com/listener for privacy information.

    12 min

  7. 1 NOV

    Drug pricing and the 2024 presidential election

    As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.   While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.   In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.   To learn more about the topics in this episode:  With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate Biden touts drug pricing achievements as he steps down from reelection campaign 2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma See omnystudio.com/listener for privacy information.

    17 min
  8. Discover Turbine’s way to build avatars true to patient biology [Sponsored]

    28 OCT

    Discover Turbine’s way to build avatars true to patient biology [Sponsored]

    Explore how Turbine AI is revolutionizing drug development by tackling biases in data for more effective cancer treatments.

    18 min
See All (100)

About

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Information

  • Creator
    Fierce Life Sciences
  • Years Active
    2023 - 2024
  • Episodes
    100
  • Rating
    Clean
  • Show Website
    The Top Line

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada